CDMRP: Neurofibromatosis Research Program
The FY26 Defense Appropriations Act provides funding for the NFRP to support innovative, high-impact research with clinical relevance that will improve the understanding, diagnosis and treatment Neurofibromatosis and schwannomatosis to enhance the quality of life for persons with these disorders that impact Service Members, their Families, Veterans and the American public. As part of the DHA R&D-MRDC, the CDMRP is the program office managing these anticipated FY26 funding opportunities.
The NFRP provides the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY26 funding opportunities.
Applications submitted to the FY26 NFRP must address one or more of the following areas of emphasis:
- NF2 and non-NF2 schwannomatosis-related areas, e.g., hearing, balance, schwannoma, ependymoma, meningioma, LZTR1, SMARCB1
- Endpoint validation, biomarker discovery and technological innovation for assessments
- Application of data science
- Non-tumor manifestations not limited to:
- Pain
- Cognitive manifestations
- Sleep
- Heterogeneity of NF-related phenotypes
- Genetics, genomics, epigenetics, systems biology, metabolomics or similar approaches
- Preclinical efficacy studies
- Target identification and drug discovery
- Nutritional, environmental and other modifiers of NF
- Health services research
Five award mechanisms are available:
- Exploration-Hypothesis Development Award
- Investigator-Initiated Research Award
- Neurofibromatosis Research Academy -- Leadership Award
- Neurofibromatosis Research Academy -- Scholar Award
- Synergistic Idea Award
Before full application submission, the CDMRP requires submission of a pre-application through the electronic Biomedical Research Application Portal, eBRAP, prior to the pre-application deadline.